KR102484396B1 - 아데노-관련된 바이러스 인자 viii 벡터 - Google Patents
아데노-관련된 바이러스 인자 viii 벡터 Download PDFInfo
- Publication number
- KR102484396B1 KR102484396B1 KR1020167009492A KR20167009492A KR102484396B1 KR 102484396 B1 KR102484396 B1 KR 102484396B1 KR 1020167009492 A KR1020167009492 A KR 1020167009492A KR 20167009492 A KR20167009492 A KR 20167009492A KR 102484396 B1 KR102484396 B1 KR 102484396B1
- Authority
- KR
- South Korea
- Prior art keywords
- aav
- bases
- vector
- fviii
- construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000301 factor viii Drugs 0.000 title claims abstract description 197
- 239000013598 vector Substances 0.000 title claims abstract description 165
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 21
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 200
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 200
- 239000013607 AAV vector Substances 0.000 claims description 125
- 150000007523 nucleic acids Chemical class 0.000 claims description 79
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 241000701447 unidentified baculovirus Species 0.000 claims description 41
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 38
- 241000238631 Hexapoda Species 0.000 claims description 35
- 230000003612 virological effect Effects 0.000 claims description 35
- 239000002245 particle Substances 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 21
- 210000004185 liver Anatomy 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 9
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 9
- 208000009292 Hemophilia A Diseases 0.000 claims description 9
- 230000008488 polyadenylation Effects 0.000 claims description 8
- 238000001890 transfection Methods 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 210000000234 capsid Anatomy 0.000 claims description 6
- 108700026244 Open Reading Frames Proteins 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 230000002103 transcriptional effect Effects 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 4
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 208000003322 Coinfection Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 26
- 229920001184 polypeptide Polymers 0.000 abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 113
- 108020004414 DNA Proteins 0.000 description 63
- 239000003623 enhancer Substances 0.000 description 60
- 108091028043 Nucleic acid sequence Proteins 0.000 description 52
- 101710095339 Apolipoprotein E Proteins 0.000 description 40
- 102100029470 Apolipoprotein E Human genes 0.000 description 40
- 241000700605 Viruses Species 0.000 description 26
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 23
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 23
- 241000283973 Oryctolagus cuniculus Species 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 22
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102000011772 Apolipoprotein C-I Human genes 0.000 description 16
- 108010076807 Apolipoprotein C-I Proteins 0.000 description 16
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 14
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 14
- 102000053020 human ApoE Human genes 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 102000057593 human F8 Human genes 0.000 description 12
- 210000002845 virion Anatomy 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 101150044789 Cap gene Proteins 0.000 description 8
- 108091092195 Intron Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 7
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 7
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000002753 trypsin inhibitor Substances 0.000 description 7
- 108090000565 Capsid Proteins Proteins 0.000 description 6
- 102100023321 Ceruloplasmin Human genes 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 241000255789 Bombyx mori Species 0.000 description 4
- 108010014173 Factor X Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 108091081021 Sense strand Proteins 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091023045 Untranslated Region Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 101150066583 rep gene Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 2
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 2
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 2
- 241000256173 Aedes albopictus Species 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 241001203868 Autographa californica Species 0.000 description 2
- 230000003682 DNA packaging effect Effects 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 102000051631 human SERPINA1 Human genes 0.000 description 2
- 229960000900 human factor viii Drugs 0.000 description 2
- -1 i.e. Proteins 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012107 replication analysis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000490515 Ascalapha odorata Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
- 102100029087 Hepatocyte nuclear factor 6 Human genes 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 1
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
- 101000988619 Homo sapiens Hepatocyte nuclear factor 6 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000930477 Mus musculus Albumin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229940036647 xyntha Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
도 2는 프로토 1, 프로토 1S, 프로토 2S 및 프로토 3S 벡터의 도식 및 서열을 제공한다. (A) 프로토 1 벡터의 도식. UCL SQ 벡터 (도 1 참고)로부터 시작하여, 외부 야생형 AAV2 바이러스 서열이 결실되었고, 인간 AAT 5' UTR 및 인간 FVIII 코딩 영역 사이의 제한 부위, 및 인간 FVIII 종료 코돈 및 합성 폴리아데닐화 서열 사이의 제한 부위에 상응하는 서열들이 제거되었다. (B) 프로토 1S 벡터의 도식. 프로토 1 벡터로부터 시작하여, AAV2 5'ITR의 3' 말단에 있는 10개의 염기 및 3' ITR의 5' 말단에 있는 10개의 염기가 결실되었다. (C) 프로토 2S 벡터의 도식. 프로토 1S 벡터로부터 시작하여, 인간 ApoE/C1 인핸서 및 인간 AAT 프로모터 원위 X 영역이 인간 FVIII 서열의 엑손 1 및 2 사이에 삽입된 100개 염기의 합성 인트론 내로 이동되었다. 화살표로 표시된 바와 같이, 인간 ApoE/C1 인핸서 및 인간 AAT 프로모터 원위 X 영역의 방향은 프로토 1S에서의 방향과 비교하여 역전되어 있다. (D) 프로토 3S 벡터의 도식. 프로토 2S로부터 시작하여, 인간 AAT 프로모터 원위 X 영역이 역방향으로 인간 ApoE/C1 인핸서의 제2 카피에 의해 치환되어 있다.
도 3은 프로토 4, 프로토 5, 프로토 6 및 프로토 7 벡터의 도식을 제공한다. (A) 프로토 4 벡터의 도식. 프로토 1 벡터로부터 시작하여, SQ 서열 및 a3 도메인이 결실되어 있다. (B) 프로토 5 벡터의 도식. 프로토 4 벡터로부터 시작하여, 129개의 염기 FVIII 인트론이 인간 인자 VIII 서열의 엑손 1 및 2 사이에 삽입되었다. (C) 프로토 6 벡터의 도식. 프로토 5 벡터로부터 시작하여, 인간 ApoE/C1 인핸서의 제2 카피가 순방향으로 FVIII 인트론 내로 삽입되었다. (D) 프로토 7 벡터의 도식. 프로토 5 벡터로부터 시작하여, 인간 ApoE/C1 인핸서의 제2 카피가 역방향으로 FVIII 인트론 내로 삽입되었다.
도 4A-도 4KK는 개선된 프로모터/인핸서 서열을 갖는 AAV FVIII 벡터의 도식을 제공한다. (A) 작제물 100ATG의 도식. (B) 작제물 100ATG bGH polyA의 도식. (C) 작제물 100ATG 짧은 bGH poly A의 도식. (D) 작제물 103ATG의 도식. (E) 작제물 103ATG 짧은 bGH poly A의 도식. (F) 작제물 105ATG bGH polyA의 도식. (G) 작제물 DC172ATG FVIII의 도식. (H) 작제물 DC172ATG FVIII hAAT의 도식. (I) 작제물 DC172 2xHCR ATG FVIII의 도식. (J) 작제물 DC172 2xHCR ATG FVIII hAAT의 도식. (K) 작제물 2x 세르핀A hAAT ATG FVIII의 도식. (L) 작제물 2x 세르핀A hAAT ATG FVIII 2x μ-글로불린 인핸서의 도식. (M) 작제물 100ATG 짧은 bGH poly A 2x μ-글로불린 인핸서의 도식. (N) 작제물 인자 VIII-BMN001의 도식. (O) 작제물 FVIII-BMN002의 도식. (P) 작제물 99의 도식. (Q) 작제물 100의 도식. (R) 작제물 100 역방향의 도식. (S) 작제물 100AT의 도식. (T) 작제물 100AT 2x MG의 도식. (U) 작제물 100AT 2x MG bGH polyA의 도식. (V) 작제물 100AT 2x MG (역) bGH poly A의 도식. (W) 작제물 100 bGH poly A의 도식. (X) 작제물 100-400의 도식. (Y) 작제물 101의 도식. (Z) 작제물 102의 도식. (AA) 작제물 103의 도식. (BB) 작제물 103 역방향의 도식 (CC) 작제물 103AT의 도식. (DD) 작제물 103AT 2x MG의 도식. (EE) 작제물 103AT 2x MG bGH poly A의 도식. (FF) 103 sbGH poly A의 도식. (GG) 작제물 104의 도식. (HH) 작제물 105의 도식. (II) 작제물 106의 도식. (JJ) 작제물 106AT의 도식. (KK) 작제물 2x 세르핀A hAAT의 도식.
도 5는 Rag2 마우스에서 프로토 작제물의 결과를 제공하며, 프로토 1은 야생형과 유사하게 FVIII을 전달함을 입증한다.
도 6 및 7은 프로토 1, 프로토 1S, 프로토 2S 및 프로토 3S가 VP1, VP2 및 VP3 단백질을 발현하고 (도 5), VP1, VP2 및 VP3 DNA를 발현하는 것 (도 6)을 입증한다.
도 8-10은 개선된 프로모터 작제물이 FVIII의 발현을 증가시킨다는 것을 입증한다.
Claims (16)
- 간-특이적 전사 조절 영역 및 코돈-최적화된 기능적 활성 FVIII 코딩 영역을 포함하는 핵산을 포함하며, 상기 기능적 활성 FVIII 코딩 영역은 서열번호 9의 뉴클레오타이드 923-5296을 포함하고, 벡터의 길이가 5.0kb 미만인, 아데노-관련된 바이러스 (AAV) 인자 VIII (FVIII) 벡터.
- 제1항에 있어서, 상기 벡터는 AAV2로부터의 AAV 5' 역전된 말단 반복 (ITR) 및 AAV 3' ITR 중 적어도 하나, 및 폴리아데닐화 서열을 포함하는 핵산을 포함하는, AAV FVIII 벡터.
- 제2항에 있어서, 상기 벡터는 인트론을 더 포함하는, AAV FVIII 벡터.
- 제1항에 있어서, 상기 간-특이적 전사 조절 영역은 서열번호 1의 뉴클레오타이드 146-397을 포함하는, AAV FVIII 벡터.
- 제1항에 있어서, 상기 간-특이적 전사 조절 영역은 서열번호 1의 뉴클레오타이드 146-397로 이루어지는, AAV FVIII 벡터.
- 삭제
- 제1항에 있어서, 상기 핵산은 서열번호 1-4의 핵산 서열로 이루어진 군으로부터 선택된 뉴클레오타이드 서열을 포함하는, AAV FVIII 벡터.
- 하기의 단계들을 포함하는, 재조합 아데노-관련된 바이러스 (AAV) 입자를 생산하는 방법:
A) 제1항 내지 제5항 및 제7항 중 어느 한 항의 AAV 벡터로 형질감염된 세포를 배양하는 단계; 및
B) 재조합 AAV 입자를 상기 형질감염된 세포의 상청액으로부터 회수하는 단계. - 제8항에 있어서, 상기 세포는 곤충 세포인, 방법.
- 제9항에 있어서, 상기 곤충 세포는 Sf9 세포인, 방법.
- 제8항에 있어서, 상기 AAV FVIII 벡터로 형질감염된 세포의 형질감염은 상기 AAV FVIII 벡터를 포함하는 바큘로바이러스에 의해 상기 세포가 감염되는 것인, 방법.
- 제8항에 있어서, 상기 AAV FVIII 벡터로 형질감염된 세포의 형질감염은 AAV rep 및 cap 유전자를 포함하는 제2 벡터와의 공동감염인, 방법.
- 제8항에 따른 방법에 의해 제조된 재조합 아데노-관련 바이러스 (AAV) 입자.
- 제13항에 있어서, AAV5 캡시드를 포함하는, 재조합 AAV 입자.
- 제1항 내지 제5항 및 제7항 중 어느 한 항의 AAV 바이러스 벡터를 포함하는 바이러스 입자.
- 혈우병 A를 치료하기 위한, 제1항 내지 제5항 및 제7항 중 어느 한 항의 AAV FVIII 벡터를 포함하는 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227046233A KR20230006058A (ko) | 2013-09-12 | 2014-09-10 | 아데노-관련된 바이러스 인자 viii 벡터 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361877042P | 2013-09-12 | 2013-09-12 | |
US61/877,042 | 2013-09-12 | ||
PCT/US2014/054960 WO2015038625A1 (en) | 2013-09-12 | 2014-09-10 | Adeno-associated virus factor viii vectors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020227046233A Division KR20230006058A (ko) | 2013-09-12 | 2014-09-10 | 아데노-관련된 바이러스 인자 viii 벡터 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160049015A KR20160049015A (ko) | 2016-05-04 |
KR102484396B1 true KR102484396B1 (ko) | 2023-01-04 |
Family
ID=51585244
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020167009492A Active KR102484396B1 (ko) | 2013-09-12 | 2014-09-10 | 아데노-관련된 바이러스 인자 viii 벡터 |
KR1020227046233A Ceased KR20230006058A (ko) | 2013-09-12 | 2014-09-10 | 아데노-관련된 바이러스 인자 viii 벡터 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020227046233A Ceased KR20230006058A (ko) | 2013-09-12 | 2014-09-10 | 아데노-관련된 바이러스 인자 viii 벡터 |
Country Status (33)
Country | Link |
---|---|
US (5) | US9504762B2 (ko) |
EP (2) | EP3044231B1 (ko) |
JP (4) | JP6735672B2 (ko) |
KR (2) | KR102484396B1 (ko) |
CN (2) | CN105636981B (ko) |
AR (1) | AR097657A1 (ko) |
AU (1) | AU2014318890B2 (ko) |
CA (3) | CA2921232C (ko) |
CL (1) | CL2016000502A1 (ko) |
CY (2) | CY1124213T1 (ko) |
DK (1) | DK3044231T3 (ko) |
ES (1) | ES2813698T3 (ko) |
FI (1) | FIC20230007I1 (ko) |
FR (1) | FR23C1007I2 (ko) |
HR (1) | HRP20201324T1 (ko) |
HU (2) | HUE050484T2 (ko) |
IL (2) | IL244404B (ko) |
LT (2) | LT3044231T (ko) |
MX (2) | MX386802B (ko) |
NL (1) | NL301222I2 (ko) |
NO (1) | NO2023003I1 (ko) |
NZ (1) | NZ716549A (ko) |
PE (1) | PE20160769A1 (ko) |
PH (1) | PH12016500328A1 (ko) |
PL (1) | PL3044231T3 (ko) |
PT (1) | PT3044231T (ko) |
RS (1) | RS61039B1 (ko) |
RU (1) | RU2710307C2 (ko) |
SG (1) | SG11201601932UA (ko) |
SI (1) | SI3044231T1 (ko) |
SM (1) | SMT202000458T1 (ko) |
TW (1) | TWI632239B (ko) |
WO (1) | WO2015038625A1 (ko) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201210357D0 (en) | 2012-06-12 | 2012-07-25 | Ucl Business Plc | Factor VIII sequences |
JP6735672B2 (ja) | 2013-09-12 | 2020-08-05 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第viii因子ベクター |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
JP6401871B2 (ja) | 2014-11-05 | 2018-10-10 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | パーキンソン病の治療のためのaadcポリヌクレオチド |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
US11007280B2 (en) | 2015-03-17 | 2021-05-18 | Vrije Universiteit Brussel | Optimized liver-specific expression systems for FVIII and FIX |
TWI707951B (zh) * | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
US10058624B2 (en) * | 2015-04-16 | 2018-08-28 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
AU2016326602A1 (en) * | 2015-09-24 | 2018-03-29 | Biomarin Pharmaceutical Inc. | Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same |
AU2016343887B2 (en) * | 2015-10-28 | 2023-04-06 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
TWI777175B (zh) * | 2015-11-13 | 2022-09-11 | 日商武田藥品工業股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體之病毒載體 |
BR112018009732A8 (pt) | 2015-11-13 | 2019-02-26 | Baxalta GmbH | ?polinucleotídeo, vetor de vírus adeno-associado, partícula de vírus adeno-associado, célula hospedeira, métodos para produzir uma partícula de vírus adeno-associado, para tratar hemofilia a, para transduzir uma célula hospedeira, e, uso de uma partícula de vírus adeno-associado? |
CN109562191A (zh) * | 2016-04-15 | 2019-04-02 | 宾夕法尼亚州大学信托人 | 用于治疗血友病a的基因疗法 |
CN109153978B (zh) * | 2016-05-25 | 2022-12-06 | 隆萨休斯敦股份有限公司 | 使用聚二烯丙基二烷基铵盐分离腺相关病毒的方法 |
JP6994018B2 (ja) | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
CN111163796A (zh) * | 2017-08-01 | 2020-05-15 | 星火治疗有限公司 | 因子viii(fviii)基因治疗方法 |
PE20210112A1 (es) | 2018-05-09 | 2021-01-19 | Biomarin Pharm Inc | Metodos de tratamiento de fenilcetonuria |
EP3794112A1 (en) | 2018-05-14 | 2021-03-24 | BioMarin Pharmaceutical Inc. | Stable expression of aav vectors in juvenile subjects |
TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
AU2019268330A1 (en) | 2018-05-15 | 2020-11-26 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
US12091675B2 (en) | 2018-07-16 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression |
WO2020020475A1 (en) * | 2018-07-27 | 2020-01-30 | Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh | Improved concepts for the treatment of genetic disorders with high-capacity plal-generated gold nanoparticles |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
SG11202103151RA (en) | 2018-09-28 | 2021-04-29 | Voyager Therapeutics Inc | Frataxin expression constructs having engineered promoters and methods of use thereof |
CA3116283A1 (en) * | 2018-10-12 | 2020-04-16 | Genzyme Corporation | Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy |
TWI851647B (zh) * | 2019-01-16 | 2024-08-11 | 日商武田藥品工業股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
MA54951A (fr) | 2019-02-15 | 2021-12-22 | Bayer Healthcare Llc | Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée |
BR112021017853A2 (pt) * | 2019-03-13 | 2021-11-30 | Generation Bio Co | Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii |
JP6831943B1 (ja) | 2019-10-24 | 2021-02-17 | 三ツ星ベルト株式会社 | 摩擦伝動ベルトおよびその製造方法 |
CN114829389A (zh) * | 2019-11-01 | 2022-07-29 | 自由行疗法有限公司 | 转录调节元件 |
WO2021097157A1 (en) * | 2019-11-14 | 2021-05-20 | Biomarin Pharmaceutical Inc. | Treatment of hereditary angioedema with liver-specific gene therapy vectors |
EP4069269A4 (en) * | 2019-12-06 | 2023-12-27 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION |
EP4073106A2 (en) | 2019-12-12 | 2022-10-19 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
WO2021236908A2 (en) | 2020-05-20 | 2021-11-25 | Biomarin Pharmaceutical Inc. | Use of regulatory proteins for the production of adeno-associated virus |
CA3183557A1 (en) | 2020-06-24 | 2021-12-30 | Bioverativ Therapeutics Inc. | Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein |
AU2021372262B9 (en) | 2020-11-02 | 2025-05-15 | Biomarin Pharmaceutical Inc. | Process for enriching adeno-associated virus |
US20240269241A1 (en) | 2021-06-14 | 2024-08-15 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
JP2023002483A (ja) * | 2021-06-22 | 2023-01-10 | ファイザー・インク | 昆虫細胞におけるアデノ随伴ウイルスベクターの産生 |
AU2022317647A1 (en) * | 2021-07-28 | 2024-01-25 | Biomarin Pharmaceutical Inc. | Large scale adeno-associated virus production systems |
KR20240049332A (ko) * | 2021-08-23 | 2024-04-16 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 인자 viii 유전자 |
WO2023036054A2 (en) * | 2021-09-08 | 2023-03-16 | Inspirar Limited | Composition and method for treating hemophilia |
EP4463475A2 (en) | 2022-01-14 | 2024-11-20 | Anjarium Biosciences AG | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
US20230374546A1 (en) * | 2022-03-11 | 2023-11-23 | Homology Medicines, Inc. | Bidirectional dual promoter expression vectors and uses thereof |
WO2023205300A2 (en) * | 2022-04-20 | 2023-10-26 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii |
WO2024064863A2 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
WO2024064856A1 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of cardiomyopathy with aav gene therapy vectors |
CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
CN118715025A (zh) * | 2022-10-08 | 2024-09-27 | 凌意(杭州)生物科技有限公司 | 用于增强基因表达的构建体 |
CN116555266B (zh) * | 2023-06-09 | 2024-11-12 | 呈诺再生医学科技(北京)有限公司 | 肝脏特异性表达的重组启动子和载体及其在肝脏相关疾病治疗中的应用 |
WO2025008774A1 (en) | 2023-07-05 | 2025-01-09 | Takeda Pharmaceutical Company Limited | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
CN118064436B (zh) * | 2024-04-18 | 2024-07-26 | 上海凌医生物科技有限公司 | 一种增强基因表达的嵌合启动子 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011005968A1 (en) | 2009-07-08 | 2011-01-13 | Ucl Business Plc | Codon-optimized factor vi i i variants and synthetic liver-specific promoter |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE78293T1 (de) | 1983-05-27 | 1992-08-15 | Texas A & M Univ Sys | Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
DK518384A (da) | 1984-01-31 | 1985-07-01 | Idaho Res Found | Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse |
WO1995002697A1 (fr) | 1993-07-13 | 1995-01-26 | Rhone-Poulenc Rorer S.A. | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
JP2001500376A (ja) | 1996-09-06 | 2001-01-16 | カイロン コーポレイション | 組換えaavベクターを使用する治療分子の肝臓特異的送達のための方法および組成物 |
AU5689699A (en) * | 1998-08-24 | 2000-03-14 | Uab Research Foundation | Methods of producing high titer recombinant adeno-associated virus |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
WO2003074714A1 (en) | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
ATE549037T1 (de) | 2004-09-22 | 2012-03-15 | St Jude Childrens Res Hospital | Verbesserte expression von faktor-ix in gentherapie-vektoren |
CN1286981C (zh) * | 2004-11-30 | 2006-11-29 | 华中科技大学同济医学院附属同济医院 | 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法 |
EP1739179A1 (en) * | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
US7943379B2 (en) | 2008-04-30 | 2011-05-17 | Nationwide Children's Hospital, Inc. | Production of rAAV in vero cells using particular adenovirus helpers |
KR20140083035A (ko) * | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | 인자 viii의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용 |
CN103215308B (zh) * | 2013-02-01 | 2015-12-23 | 中国科学院苏州生物医学工程技术研究所 | 表达重组人fviii的整合质粒、细胞株及其构建方法和应用 |
JP6735672B2 (ja) * | 2013-09-12 | 2020-08-05 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第viii因子ベクター |
-
2014
- 2014-09-10 JP JP2016542067A patent/JP6735672B2/ja active Active
- 2014-09-10 PT PT147717292T patent/PT3044231T/pt unknown
- 2014-09-10 KR KR1020167009492A patent/KR102484396B1/ko active Active
- 2014-09-10 SG SG11201601932UA patent/SG11201601932UA/en unknown
- 2014-09-10 PL PL14771729T patent/PL3044231T3/pl unknown
- 2014-09-10 CN CN201480050615.3A patent/CN105636981B/zh active Active
- 2014-09-10 KR KR1020227046233A patent/KR20230006058A/ko not_active Ceased
- 2014-09-10 CA CA2921232A patent/CA2921232C/en active Active
- 2014-09-10 LT LTEP14771729.2T patent/LT3044231T/lt unknown
- 2014-09-10 MX MX2016003262A patent/MX386802B/es unknown
- 2014-09-10 ES ES14771729T patent/ES2813698T3/es active Active
- 2014-09-10 RU RU2016113702A patent/RU2710307C2/ru active
- 2014-09-10 HU HUE14771729A patent/HUE050484T2/hu unknown
- 2014-09-10 SM SM20200458T patent/SMT202000458T1/it unknown
- 2014-09-10 CA CA3178379A patent/CA3178379A1/en active Pending
- 2014-09-10 SI SI201431647T patent/SI3044231T1/sl unknown
- 2014-09-10 PE PE2016000353A patent/PE20160769A1/es unknown
- 2014-09-10 NZ NZ716549A patent/NZ716549A/en unknown
- 2014-09-10 CN CN202011117582.3A patent/CN112538501A/zh active Pending
- 2014-09-10 EP EP14771729.2A patent/EP3044231B1/en active Active
- 2014-09-10 HR HRP20201324TT patent/HRP20201324T1/hr unknown
- 2014-09-10 WO PCT/US2014/054960 patent/WO2015038625A1/en active Application Filing
- 2014-09-10 RS RS20201018A patent/RS61039B1/sr unknown
- 2014-09-10 AU AU2014318890A patent/AU2014318890B2/en active Active
- 2014-09-10 EP EP20182970.2A patent/EP3770169A1/en active Pending
- 2014-09-10 US US14/482,648 patent/US9504762B2/en active Active
- 2014-09-10 CA CA3178384A patent/CA3178384A1/en active Pending
- 2014-09-10 DK DK14771729.2T patent/DK3044231T3/da active
- 2014-09-12 AR ARP140103423A patent/AR097657A1/es not_active Application Discontinuation
- 2014-09-12 TW TW103131665A patent/TWI632239B/zh active
-
2016
- 2016-02-18 PH PH12016500328A patent/PH12016500328A1/en unknown
- 2016-03-03 IL IL244404A patent/IL244404B/en unknown
- 2016-03-04 CL CL2016000502A patent/CL2016000502A1/es unknown
- 2016-03-11 MX MX2021012014A patent/MX2021012014A/es unknown
- 2016-10-14 US US15/294,310 patent/US10463718B2/en active Active
-
2017
- 2017-11-17 US US15/816,596 patent/US20180161403A1/en not_active Abandoned
-
2019
- 2019-08-14 JP JP2019148912A patent/JP7523211B2/ja active Active
- 2019-09-30 US US16/588,130 patent/US11406690B2/en active Active
-
2020
- 2020-08-31 CY CY20201100814T patent/CY1124213T1/el unknown
-
2021
- 2021-02-18 JP JP2021024332A patent/JP2021072871A/ja not_active Withdrawn
- 2021-09-30 IL IL286859A patent/IL286859A/en unknown
-
2022
- 2022-06-30 US US17/854,286 patent/US12239692B2/en active Active
-
2023
- 2023-01-11 HU HUS2300003C patent/HUS2300003I1/hu unknown
- 2023-01-12 NO NO2023003C patent/NO2023003I1/no unknown
- 2023-02-02 FR FR23C1007C patent/FR23C1007I2/fr active Active
- 2023-02-08 FI FIC20230007C patent/FIC20230007I1/fi unknown
- 2023-02-20 LT LTPA2023508C patent/LTPA2023508I1/lt unknown
- 2023-02-20 CY CY2023006C patent/CY2023006I2/el unknown
- 2023-02-24 NL NL301222C patent/NL301222I2/nl unknown
- 2023-08-04 JP JP2023127698A patent/JP2023133597A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011005968A1 (en) | 2009-07-08 | 2011-01-13 | Ucl Business Plc | Codon-optimized factor vi i i variants and synthetic liver-specific promoter |
US20130024960A1 (en) | 2009-07-08 | 2013-01-24 | Ucl Business Plc | Optimised coding sequence and promoter |
Non-Patent Citations (2)
Title |
---|
Blood, Vol. 121, No, 7, pp3335-3344(2013). |
MT568995.1(GenBank #) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102484396B1 (ko) | 아데노-관련된 바이러스 인자 viii 벡터 | |
AU2021261832B2 (en) | Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same | |
KR20210008491A (ko) | 청소년 대상체에서 aav 벡터의 안정한 발현 | |
CN109843930B (zh) | 酸性α-葡萄糖苷酶变体及其用途 | |
AU2023274083A1 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
KR102537394B1 (ko) | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 | |
JP2024059727A (ja) | Cns変性のための遺伝子治療法 | |
KR20160131032A (ko) | 곤충 세포에서 생산된 더욱 향상된 aav 벡터 | |
KR20210092755A (ko) | 신경원성 세로이드 리포푸신증에 대한 유전자 요법 | |
CN114929735A (zh) | 因子viii构建体 | |
KR20210053902A (ko) | 글리코겐 저장 질환 iii 의 치료를 위한 미니-gde | |
KR20220112262A (ko) | Nadh 탈수소효소 단백질을 이용한 레버 유전성 시신경병증 치료용 조성물 및 방법 | |
KR20220098210A (ko) | 간-특이적 유전자 요법 벡터를 이용한 유전성 혈관 부종의 치료 | |
KR20210068014A (ko) | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 | |
CN111902164A (zh) | 用于恢复pah基因功能的腺相关病毒组合物及其使用方法 | |
AU2021204690A1 (en) | Compositions and methods for treating Leber's hereditary optic neuropathy | |
HK40050537A (en) | Adeno-associated virus factor viii vectors | |
RU2777372C2 (ru) | Векторы экспрессии фактора viii на основе аденоассоциированного вируса | |
RU2792432C2 (ru) | Стабильная экспрессия векторов на основе аденоассоциированного вируса у несовершеннолетних пациентов | |
TW202302854A (zh) | 藉由異源使用選擇性剪接匣以提供基因療法貨物調控的方法及組成物 | |
HK40000312A (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
KR20230003557A (ko) | 스펙트린 융합 도메인을 갖는 소형화 디스트로핀 및 그의 용도 | |
WO2024151568A1 (en) | Epigenetic modifiers improve aav gene therapy durability | |
KR20230066453A (ko) | 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도 | |
RU2780329C2 (ru) | Варианты кислой альфа-глюкозидазы и их использование |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20160411 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190822 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200726 Patent event code: PE09021S01D |
|
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20210831 Patent event code: PE09021S02D |
|
PN2301 | Change of applicant |
Patent event date: 20220425 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220929 |
|
A107 | Divisional application of patent | ||
GRNT | Written decision to grant | ||
PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20221229 |
|
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20221229 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20221230 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |